Safety of Serum for Post-Inflammatory on Hyperpigmentation Skin

Sponsor
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre (Industry)
Overall Status
Recruiting
CT.gov ID
NCT05998200
Collaborator
(none)
34
1
1
15
2.3

Study Details

Study Description

Brief Summary

This study aims to investigate the safety of serum product containing low dose of alpha hydroxy acid (AHA) i.e. 1% Glycolic acid and Lactic acid and Polyglutamate acid derivatives (PGA) for post-inflammatory hyperpigmentation skin in Malaysia. The study duration is 8 weeks and the skin assessment will be carried out at baseline, week 4 and week 8.The main questions this study aims to answer are:

  1. To investigate the safety of serum containing low concentration AHA (1% Glycolic acid and Lactic acid) and PGA for post-inflammatory hyperpigmentation skin among Malaysian.

  2. To assess the patient satisfaction after using serum containing low concentration AHA (1% Glycolic acid and Lactic acid) and PGA among Malaysian.

Condition or Disease Intervention/Treatment Phase
  • Other: Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
34 participants
Allocation:
N/A
Intervention Model:
Single Group Assignment
Masking:
None (Open Label)
Primary Purpose:
Other
Official Title:
Safety of Serum Containing Alpha Hydroxy Acid (AHA) and Polyglutamate Acid Derivatives for Post-Inflammatory on Hyperpigmentation Skin
Actual Study Start Date :
Jul 1, 2023
Anticipated Primary Completion Date :
Jul 30, 2024
Anticipated Study Completion Date :
Sep 30, 2024

Arms and Interventions

Arm Intervention/Treatment
Other: Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA

This serum containing low concentration AHA (1% Glycolic acid and Lactic acid) and PGA.

Other: Serum with low concentration AHA (1% Glycolic acid and Lactic acid) and PGA
Participants will used the serum twice daily for 8 weeks

Outcome Measures

Primary Outcome Measures

  1. Adverse effect after using the serum. [Week 8]

    Based on adverse effect occurrence on participants that occur during study period (8 weeks)

Secondary Outcome Measures

  1. Change in skin moisture level [Baseline, Week 4 and Week 8]

    Skin moisture will be measure using JANUS III skin analyzer and the changes in skin moisture from baseline and at week 4 and week 8 will be compared.

  2. Change in skin spot level [Baseline, Week 4 and Week 8]

    Skin spot will be measure using JANUS III skin analyzer and the changes in skin spot from baseline and at week 4 and week 8 will be compared.

  3. Change in skin pores level [Baseline, Week 4 and Week 8]

    Skin pores will be measure using JANUS III skin analyzer and the changes in skin pores from baseline and at week 4 and week 8 will be compared.

  4. Change in skin tone level [Baseline, Week 4 and Week 8]

    Skin tone will be measure using JANUS III skin analyzer and the changes in skin tone from baseline and at week 4 and week 8 will be compared.

  5. Participant satisfaction after using the serum for 8 week. [Week 8]

    Participation satisfaction will be evaluated using the Physician Global Assessment (PGA) survey. The subjective score of changes in skin conditions including skin wrinkles, dryness, smoothness, moisturizing and brightening effect will be graded as follows: very satisfied, satisfied, neutral, dissatisfied, very dissatisfied.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 40 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Malaysian from 18 to 40 years old.

  • Participants with post-inflammatory hyperpigmentation (PIH).

Exclusion Criteria:
  • Participant with known systemic or skin disease and any underlying medical illness

  • Pregnant, breastfeeding women or planned pregnancy during the study period.

  • Had reported history of dermatologic conditions (i.e. Atopic dermatitis, psoriasis) or known allergies to any ingredients that may be found in the product.

  • Had any cosmetic procedures such as Botox, laser and light treatment, facial surgery, chemical peel and any procedures that may improve skin texture 1 month before the study.

  • Had history of taking isotretinoin for the past 6 or 12 month and AHA (alpha hydroxyl acids) containing products or any other products for treating hyperpigmentation skin or melasma 1 month prior to study.

Contacts and Locations

Locations

Site City State Country Postal Code
1 Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre Petaling Jaya Selangor Malaysia 47810

Sponsors and Collaborators

  • Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
ClinicalTrials.gov Identifier:
NCT05998200
Other Study ID Numbers:
  • UMRAMREC001-23
First Posted:
Aug 18, 2023
Last Update Posted:
Aug 18, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ungku Shahrin Medical Aesthetic Research & Innovation (USMARI) Centre
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 18, 2023